Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
PRQR Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: March 30, 2026
Report Source: 2025 Annual Report
ProQR Therapeutics NV. Stock Analysis PRQR
United States Health Care Micro Cap Report: ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company is headquartered in Leiden, Zuid-Holland and currently employs 187 full-time employees. The company went IPO on 2014-09-18. The firm is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The firm operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
Read More ProQR Therapeutics NV (PRQR) Chart
Key Statistics of ProQR Therapeutics NV (PRQR)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$1.81Volume
864.62KP/E Ratio (TTM)
-52 Week Range
Market Cap
151.72MAvg. Volume
575.60KDividend Yield
-Financial Metrics & Statements of ProQR Therapeutics NV (PRQR)
FAQ's for ProQR Therapeutics NV (PRQR)
- According to Musaffa’s Shariah screening methodology, ProQR Therapeutics NV (PRQR) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes ProQR Therapeutics NV using these criteria to determine its compliance status.
- Muslim investors may consider investing in ProQR Therapeutics NV if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of ProQR Therapeutics NV by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of ProQR Therapeutics NV may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of ProQR Therapeutics NV on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.